AxoGen, Inc. (NASDAQ:AXGN) Shares Purchased by New York State Common Retirement Fund

New York State Common Retirement Fund boosted its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 63.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 69,629 shares of the medical equipment provider’s stock after acquiring an additional 27,101 shares during the quarter. New York State Common Retirement Fund owned about 0.16% of AxoGen worth $1,147,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Creative Planning raised its stake in shares of AxoGen by 152.2% during the third quarter. Creative Planning now owns 29,790 shares of the medical equipment provider’s stock worth $418,000 after purchasing an additional 17,980 shares during the last quarter. Sentry Investment Management LLC raised its position in AxoGen by 9.3% during the 3rd quarter. Sentry Investment Management LLC now owns 17,368 shares of the medical equipment provider’s stock worth $243,000 after buying an additional 1,483 shares during the last quarter. Principal Financial Group Inc. acquired a new stake in shares of AxoGen in the 3rd quarter worth $207,000. Primoris Wealth Advisors LLC purchased a new stake in shares of AxoGen in the third quarter valued at about $207,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of AxoGen during the third quarter worth about $279,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

AxoGen Trading Down 3.6 %

NASDAQ:AXGN opened at $19.29 on Tuesday. The stock has a market capitalization of $855.40 million, a price-to-earnings ratio of -60.28 and a beta of 1.00. AxoGen, Inc. has a 1 year low of $5.55 and a 1 year high of $21.00. The stock has a fifty day moving average price of $17.75 and a two-hundred day moving average price of $15.11. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group raised their price objective on shares of AxoGen from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, February 26th.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.